en · de · es · fr · pt
faq-desk.peptides6155.com › Data › Background And Receptor Mechanism — Evidence Review

Background And Receptor Mechanism — Evidence Review

By Editorial Desk · published 2026-01-13 · last reviewed 2026-02-20 · Data

The short version of REV-ERB fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Related pages on this site

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Reference notes

Tetrodotoxin (TTX) is a potent neurotoxin. Its name derives from Tetraodontiformes, an order that includes pufferfish, porcupinefish, ocean sunfish, and triggerfish; several of these species carry the toxin. Although tetrodotoxin was discovered in these fish, it is found in several other animals (e.g., in blue-ringed octopuses, rough-skinned newts, and moon snails). It is also produced by certain infectious or symbiotic bacteria like Pseudoalteromonas, Pseudomonas, and Vibrio as well as other species found in symbiotic relationships with animals and plants. Although it produces thousands of intoxications annually and several deaths, it has shown efficacy for the treatment of cancer-related pain in phase II and III clinical trials. Tetrodotoxin is a sodium channel blocker. It inhibits the firing of action potentials in neurons by binding to the voltage-gated sodium channels in nerve cell membranes and blocking the passage of sodium ions (responsible for the rising phase of an action potential) into the neuron. This prevents the nervous system from carrying messages and thus muscles from contracting in response to nervous stimulation. Its mechanism of action – selective blocking of the sodium channel – was shown definitively in 1964 by Toshio Narahashi and John W. Moore at Duke University, using the sucrose gap voltage clamp technique.

=== Awards and honours === As of 2015, Sanger is one of the only two people to have been awarded the Nobel Prize in Chemistry twice (the other being Karl Barry Sharpless in 2001 and 2022), and one of only five two-time Nobel laureates: The other four were Marie Curie (Physics, 1903 and Chemistry, 1911), Linus Pauling (Chemistry, 1954 and Peace, 1962), John Bardeen (twice Physics, 1956 and 1972), and Karl Barry Sharpless (twice Chemistry, 2001 and 2022).

=== Antibody heterogeneity === Product heterogeneity is common in monoclonal antibodies and other recombinant biological products and is typically introduced either upstream during expression or downstream during manufacturing. These variants are typically aggregates, deamidation products, glycosylation variants, oxidized amino acid side chains, as well as amino and carboxyl terminal amino acid additions. These seemingly minute structural changes can affect preclinical stability and process optimization as well as therapeutic product potency, bioavailability and immunogenicity. The generally accepted purification method of process streams for monoclonal antibodies includes capture of the product target with protein A, elution, acidification to inactivate potential mammalian viruses, followed by ion chromatography, first with anion beads and then with cation beads. Displacement chromatography has been used to identify and characterize these often unseen variants in quantities that are suitable for subsequent preclinical evaluation regimens such as animal pharmacokinetic studies. Knowledge gained during the preclinical development phase is critical for enhanced product quality understanding and provides a basis for risk management and increased regulatory flexibility. The recent Food and Drug Administration's Quality by Design initiative attempts to provide guidance on development and to facilitate design of products and processes that maximizes efficacy and safety profile while enhancing product manufacturability.

Sources: en.wikipedia.org

Notes from published material

Mahathir bin Mohamad (Jawi: محاضر بن محمد; Malay: [mahade(r) muhammad, -ðe(r)] ; born 10 July 1925) is a Malaysian politician, physician and author who served as the fourth and seventh prime minister of Malaysia from 1981 to 2003 and again from 2018 to 2020. He was the country's longest-serving prime minister, serving for a cumulative total of 24 years. His political career has spanned more than 75 years, from joining protests opposing citizenship policies for non-Malays in the Malayan Union in the 1940s to forming the Gerakan Tanah Air coalition in 2022. During his premiership, Mahathir was granted the title "Father of Modernisation" (Malay: Bapa Pemodenan) for his pivotal role in transforming the country's economy and infrastructure. At 101 years old, he is the second-oldest living former state leader in the world and the first Malaysian prime minister to reach that age. Born and raised in Alor Setar, Kedah, Mahathir excelled at school and became a physician. He became active in UMNO before entering the parliament of Malaysia in 1964 as the Member of Parliament for Kota Setar Selatan, serving until he lost his seat in 1969, subsequently falling out with Prime Minister Tunku Abdul Rahman and being expelled from UMNO. In 1970, he released the book The Malay Dilemma. When Tunku resigned, Mahathir re-entered UMNO and parliament through Kubang Pasu constituency, and was promoted to Minister of Education from 1974 to 1978 and Minister of Trade and Industry from 1978 to 1981. He became deputy prime minister in 1976 before being sworn in as prime minister in 1981.

== Ecology == The Liliaceae are ecologically diverse. Species of Liliaceae bloom at various times from spring to late summer. The colorful flowers produce large amounts of nectar and pollen that attract insects which pollinate them (entomophily), particularly bees and wasps (hymenopterophily), butterflies (psychophily) and moths (phalaenophily). The seeds are dispersed by wind and water. Some species (e.g. Scoliopus, Erythronium and Gagea) have seeds with an aril structure that are dispersed by ants (myrmecochory). The proliferation of deer populations in many areas, due to human factors such as the elimination of their animal predators and introduction to alien environments, is placing considerable herbivory pressure on many of the family's species. Fences as high as 8 feet may be required to prevent them from consuming the plants, an impractical solution for most wild areas. Those of the genus Lilium are particularly palatable, while species in Fritillaria are repellant.

extrachromosomal DNA Also extranuclear DNA and cytoplasmic DNA. Any DNA that is not found in chromosomes or in the nucleus of a cell and hence is not genomic DNA. This may include the DNA contained in plasmids or organelles such as mitochondria or chloroplasts, or, in the broadest sense, DNA introduced by viral infection. Extrachromosomal DNA usually shows significant structural differences from nuclear DNA in the same organism.

Sources: en.wikipedia.org

Background from the literature

=== Cornell and later career in Athens === Photaki was selected in 1962 by the US Department of Health, Education and Welfare among an international pool of candidates to conduct research by the side of Nobel laureate Vincent du Vigneaud at Cornell University. While in New York, she also delivered a short series of lectures both in Cornell and at the National Institutes of Health (NIH). Back in the University of Athens after Cornell, Photaki continued her research and was soon habilitated in 1965 following a thesis on oxytocin, building on the work she started under du Vigneaud. Despite her internationally distinguished research and sizeable recent grants from the NHRF and the United States NIH, she was not allowed to teach by the Greek military junta until 1969 and was intensively interrogated by the Cities Police Security Directorate on account of her anti-dictatorial political beliefs. Photaki's teaching career was purposefully hindered by the Ministry of Education until the restoration of democracy in 1974; indeed, in 1975 she was promoted to extraordinary professor, a decade after receiving her habilitation. Shortly afterwards, in 1977, she was promoted to full professor (as Professor of Organic Chemistry) and Head of the Organic Chemistry Laboratory, both positions once held by her mentor Zervas. Photaki died in 1983 at the age of 62. She was reported to spend very long hours at the laboratory, occasionally from "8 in the morning till 10 in the evening".

==== CCN family ==== CCN1: Cysteine-rich angiogenic inducer 61 (CYR61) CCN2: Connective tissue growth factor (CTGF) CCN3: Nephroblastoma overexpressed (NOV) CCN4: WNT1-inducible-signaling pathway protein 1 (WISP1) CCN5: WNT1-inducible-signaling pathway protein 2 (WISP2)

An overdose of benzodiazepines can cause dangerous deep unconsciousness, but are less toxic than their predecessors, the barbiturates, and death rarely results when a benzodiazepine is the only drug taken. Combined with other central nervous system (CNS) depressants such as alcohol and opioids, the potential for toxicity and fatal overdose increases significantly. Flumazenil is generally considered a first-line treatment in benzodiazepine overdose, although its usage outside the controllable environment of medical facilities possesses great risk of developing seizures and other life-threating conditions. Benzodiazepines are commonly used recreationally and also often taken in combination with other addictive substances, and are controlled in most countries.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network